BioCentury
ARTICLE | Finance

Synthetic vitality

Why Versant, MPM chose Repare as their $68M synthetic lethality play

June 23, 2017 10:18 PM UTC

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit.

Repare emerged from stealth mode on June 22 with the $68 million tranched round, which was co-led by Versant and MPM with participation from Fonds de solidarité FTQ, the Celgene Switzerland LLC affiliate of Celgene Corp. (NASDAQ:CELG) and BDC Capital’s Healthcare Venture Fund. Details on the tranches are undisclosed. ...